Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension

FE 202158, ([Phe 2 ,Ile 3 ,Hgn 4 ,Orn(iPr) 8 ]vasopressin, where Hgn is homoglutamine and iPr is isopropyl), a peptidic analog of the vasoconstrictor hormone [Arg 8 ]vasopressin (AVP), was designed to be a potent, selective, and short-acting vasopressin type 1a receptor (V 1a R) agonist. In functional reporter gene assays, FE 202158 was a potent and selective human V 1a R agonist [EC 50 = 2.4 nM; selectivity ratio of 1:142:1107:440 versus human vasopressin type 1b receptor, vasopressin type 2 receptor (V 2 R), and oxytocin receptor, respectively] contrasting with AVP9s lack of selectivity, especially versus the V 2 R (selectivity ratio of 1:18:0.2:92; human V 1a R EC 50 = 0.24 nM). This activity and selectivity profile was confirmed in radioligand binding assays. FE 202158 was a potent vasoconstrictor in the isolated rat common iliac artery ex vivo (EC 50 = 3.6 nM versus 0.8 nM for AVP) and reduced rat ear skin blood flow after intravenous infusion in vivo (ED 50 = 4.0 versus 3.4 pmol/kg/min for AVP). The duration of its vasopressor effect by intravenous bolus in rats was as short as AVP at submaximally effective doses. FE 202158 had no V 2 R-mediated antidiuretic activity in rats by intravenous infusion at its ED 50 for reduction of ear skin blood flow, in contrast with the pronounced antidiuretic effect of AVP. Thus, FE 202158 seems suitable for treatment of conditions where V 1a R activity is desirable but V 2 R activity is potentially deleterious, such as vasodilatory hypotension in septic shock. In addition to the desirable selectivity profile, its short-acting nature should allow dose titration with rapid onset and offset of action to optimize vasoconstriction efficacy and safety.